Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients.

Trial Profile

Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Actual end date Sep 2010 added as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top